Solid Biosciences Inc.

NasdaqGS SLDB

Solid Biosciences Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -9.36 M

Solid Biosciences Inc. Net Cash Used For Investing Activities is USD -9.36 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -130.69% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Solid Biosciences Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 30.49 M, a 31.25% change year over year.
Solid Biosciences Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 23.23 M, a 119.15% change year over year.
Solid Biosciences Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -121.32 M, a -1,375.06% change year over year.
Solid Biosciences Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 9.52 M, a 2,296.73% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: SLDB

Solid Biosciences Inc.

CEO	Mr. Alexander G. Cumbo
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	141 Portland Street
Employees	88
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years